IRCT20200128046294N3招募中1 期
Safety study of Sofosbuvir 800mg and Daclatasvir 120mg in adult outpatients with COVID-19
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Age higher than 18 years old
- •Diagnosis of COVID 19
- •Patients that do not need to be admitted in hospital
排除标准
- •Patients without consent form
- •Patients that can not come for follow-up
- •Pregnancy , breast feeding
- •Renal insufficiency with eGFR less than 30 , or serum creatinin higher than 2.5 mg/dl in male and 2 mg/dl in female
- •Heart rate less than 50/ min
- •Hepatitis B infection
- •Amiodarone and /or Warfarin consumption
研究者
相似试验
已完成
不适用
Safety And Effectiveness Of Sofosbuvir And Daclatasvir In Patients Who Have Thalassemia With Hepatitis C Virus Infection And Who Are 6 years To 18 Years OldCTRI/2020/06/025910Riten Kumar Samadder70
已完成
3 期
Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patientsCOVID-19.U07.1COVID-19IRCT20200624047908N1Abadan University of Medical Sciences1,000
已完成
2 期
Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19COVID-19.2019-nCOV diseaseU07.1IRCT20200324046850N2Abadan University of Medical Sciences62
招募中
2 期
Efficacy & Safety of Sofosbuvir/Daclatasvir treatment in COVID-19: A randomized, controlled studyCOVID-19SARS-nCoV-2 infectionDRKS00022203PHARCO CORPORATE90
已完成
不适用
Sofosbuvir and Daclatasvir for treatment of Hepatitis-C in patients undergoing hemodialysis.IRCT20170614034526N3Jinnah Hospital, Lahore36